Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lonapegsomatropin (Skytrofa) vs Tesamorelin
An educational, source-based comparison of Lonapegsomatropin (Skytrofa) and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)
- • FDA-approved only for HIV-associated lipodystrophy.
- • May affect glucose tolerance; monitor in at-risk patients.
- • Requires physician oversight.
Lonapegsomatropin (Skytrofa) vs Tesamorelin — Key differences
- Class: Lonapegsomatropin (Skytrofa) is classified as GH Analog · Endocrine, while Tesamorelin is Growth Hormone Axis.
- Primary research focus: Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency; Tesamorelin — visceral adipose tissue reduction (approved).
- Tag: FDA-Approved · Endocrine vs Body composition.